| Literature DB >> 31193177 |
C Rodriguez1, B Taminiau1, L Bouchafa1, S Romijn2, J Van Broeck3, M Delmée3, C Clercx2, G Daube1.
Abstract
Zoonotic transmission of Clostridium difficile has been largely hypothesised to occur after direct or indirect contact with contaminated animal faeces. Recent studies have reported the presence of the bacterium in the natural environment, including in soils and rivers. If C. difficile spores are scattered in the environment, they can easily enter the respiratory tract of dogs, and therefore, dog nasal discharge could be a direct route of transmission not previously investigated. This study reports for the first time the presence of C. difficile in the respiratory tracts of dogs. The bacterium was isolated from 6 (17.1%) out of 35 nasal samples, with a total of 4 positive dogs (19%). C. difficile was recovered from both proximal and distal nasal cavities. All isolates were toxigenic and belonged to PCR-ribotype 014, which is one of the most predominant types in animals and in community-acquired C. difficile infections in recent years. The findings of this study demonstrate that the nasal cavity of dogs is contaminated with toxigenic C. difficile, and therefore, its secretions could be considered as a new route by which bacteria are spread and transmitted.Entities:
Keywords: Microbiology; Zoology
Year: 2019 PMID: 31193177 PMCID: PMC6520566 DOI: 10.1016/j.heliyon.2019.e01629
Source DB: PubMed Journal: Heliyon ISSN: 2405-8440
Detailed clinical data of dogs enrolled in the study.
| Origin | Animal ID | Breed | Genre | Weight (Kg) | Hospitalization/Consultation | Date of naissance | Consultation/illness | Medical treatment |
|---|---|---|---|---|---|---|---|---|
| Belgium | AA | French Bulldog | Female | 10 | Consultation | 19.11.2013 | BAOS, Small nostrils Breathing difficulties | NTR |
| AB | French Bulldog | Male | 11 | Consultation | 02.12.2014 | BAOS, Breathing difficulties | NTR | |
| AC | Malinois | Male | 30 approx. | Consultation | 14.07.2014 | Stress intolerance | Biclar 500mg 1x/day | |
| AD | French Bulldog | Male | 15 | Consultation | 24.03.2015 | BAOS, Post-operatory consultation | Sedacid 20 mg: ¾ tablet BID | |
| AE | French Bulldog | Female | 11 | Consultation | 13.05.2016 | BAOS | NTR | |
| AF | French Bulldog | Male | 11 approx. | Consultation | 06.03.2016 | Cough | Omeprazole 1 mg/kg SID | |
| AG | Free-ranging dog | Male | 38 | Consultation | 27.04.2004 | Laryngeal paralysis | Dexamethasone SC Codeine PO | |
| AH | Westie | Female | 10.1 | Consultation | 03.05.2004 | Pulmonary fibrosis | Amoxyclav for 2 weeks | |
| AI | French Bulldog | Male | 10 approx. | Consultation | 01.10.2012 | BAOS | Prednisolone 0.5 mg/Kg BID | |
| AJ | Free-ranging dog | Female | NAD | Consultation | 21.06.2011 | Sneeze | Amoxyclav for 3 weeks | |
| AK | Border Collie | Male | 17 | Consultation | 01.03.2008 | Cordvocalectomy control | Prednisolone 0.5mg/Kg BID | |
| AL | French Bulldog | Male | 10.7 | Consultation | 01.01.2013 | BAOS | Omeprazole 10 mg/kg BID | |
| AM | French Bulldog | Male | 10.5 | Hospitalization 1 day | 01.01.2010 | BAOS | NAD | |
| Finland | BA | Westie | Male | 10 approx. | Consultation | 10.01.2009 | Idiopathic pulmonary fibrosis | NAD |
| BB | Westie | Male | 10 approx. | Consultation | 18.11.2009 | Idiopathic pulmonary fibrosis | NAD | |
| BC | Westie | Female | 10 approx. | Consultation | 28.01.2009 | Idiopathic pulmonary fibrosis | NAD | |
| BD | Westie | Male | 10 approx. | Consultation | 19.05.2011 | Idiopathic pulmonary fibrosis | NAD | |
| BE | Westie | Male | 10 approx. | Consultation | 18.05.2017 | Idiopathic pulmonary fibrosis | NAD | |
| BF | Westie | Female | 10 approx. | Consultation | 21.05.2014 | Idiopathic pulmonary fibrosis | NAD | |
| BG | Westie | Male | 10 approx. | Consultation | 18.11.2009 | Idiopathic pulmonary fibrosis | NAD | |
| BH | Westie | Male | 10 approx. | Consultation | 16.10.2008 | Idiopathic pulmonary fibrosis | NAD |
Animal ID: Animal identification; Malinois: Belgian Shepherd Malinois; Westie: West Highland white terrier; BAOS: Brachycephalic airway obstructive syndrome.
NTR: not treatment registered; NDA: not available data; BID: bis in die (two times per day); SID: sem' el in di'e (once a day).
Antibiotic treatment, anti-acid treatment or others.
Treatment at the moment of sampling.
Treatment between 2 months and 2 weeks before sampling.
Detailed information about the positive and negative samples for C. difficile and molecular characterization of the isolates.
| Animal ID | Sampling date | Type of sample | PCR-Ribotype | Cytotoxic activity | Toxin Profile | |||
|---|---|---|---|---|---|---|---|---|
| AA | 18.04.2017 | Left proximal nasal cavity | ND | − | − | − | ||
| AB | 18.04.2017 | Right proximal nasal cavity | Positive | 014 | + | + | + | − |
| Left proximal nasal cavity | Positive | 014 | + | + | + | − | ||
| AC | 25.04.2017 | Right proximal nasal cavity | Positive | 014 | + | + | + | − |
| Right distal third of the nasal cavity | Positive | O14 | + | + | + | − | ||
| AD | 27.04.2017 | Right proximal nasal cavity | Positive | 014 | + | + | + | − |
| Left proximal nasal cavity | ND | − | − | − | ||||
| AE | 27.04.2017 | Left proximal nasal cavity | Positive | 014 | + | + | + | − |
| AF | 02.05.2017 | Right proximal nasal cavity | ND | − | − | − | ||
| Left proximal nasal cavity | ND | − | − | − | ||||
| AG | 03.05.2017 | Left proximal nasal cavity | ND | − | − | − | ||
| Left distal third of the nasal cavity | ND | − | − | − | ||||
| AH | 05.05.2017 | Right proximal nasal cavity | ND | − | − | − | ||
| Left proximal nasal cavity | ND | − | − | − | ||||
| AI | 16.05.2017 | Left proximal nasal cavity | ND | − | − | − | ||
| Left distal third of the nasal cavity | ND | − | − | − | ||||
| AJ | 06.06.2017 | Left proximal nasal cavity | ND | − | − | − | ||
| Left distal third of the nasal cavity | ND | − | − | − | ||||
| AK | 06.06.2017 | Left proximal nasal cavity | ND | − | − | − | ||
| Left distal third of the nasal cavity | ND | − | − | − | ||||
| AL | 06.06.2017 | Left proximal nasal cavity | ND | − | − | − | ||
| Left distal third of the nasal cavity | ND | − | − | − | ||||
| AM | 13.06.2017 | Right proximal nasal cavity | ND | − | − | − | ||
| Right distal third of the nasal cavity | ND | − | − | − | ||||
| BA | 22.06.2017 | Bronchoalveolar lavage fluid (right side) | ND | − | − | − | ||
| BB | 22.06.2017 | Bronchoalveolar lavage fluid (left side) | ND | − | − | − | ||
| BC | 22.06.2017 | Bronchoalveolar lavage fluid (right side) | ND | − | − | − | ||
| BD | 22.06.2017 | Bronchoalveolar lavage fluid (left side) | ND | − | − | − | ||
| Bronchoalveolar lavage fluid (right side) | ND | − | − | − | ||||
| BE | 22.06.2017 | Bronchoalveolar lavage fluid (left side) | ND | − | − | − | ||
| Bronchoalveolar lavage fluid (right side) | ND | − | − | − | ||||
| BF | 22.06.2017 | Bronchoalveolar lavage fluid (left side) | ND | − | − | − | ||
| Bronchoalveolar lavage fluid (right side) | ND | − | − | − | ||||
| BG | 22.06.2017 | Bronchoalveolar lavage fluid (right side) | ND | − | − | − | ||
| BH | 22.06.2017 | Bronchoalveolar lavage fluid (right side) | ND | − | − | − | ||
ND: No detection.
Samples received from other external clinic at −80 °C. Date of sample defrosting and analysis.